Health Economics›Soft tissue sarcoma›Locally advanced or metastatic disease single-agent regimens

Locally advanced or metastatic disease single-agent regimens

Soft tissue sarcoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #06	—	R 307 423	28d	~4.3 mo	—	~5	~R 1 537 113 PFS proxy · indirect	4
Pazopanib monotherapy Variant #01	—	R 22 754	28d	4.6 mo	—	6	R 136 521 PFS proxy	1
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	~4.0 mo	~8.4 mo	~5	~R 49 173 PFS proxy · indirect	2
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~4.0 mo	~16.3 mo	~5	~R 40 764 PFS proxy · indirect	10
Epirubicin monotherapy Variant #01	—	R 2 611	21d	~8.2 mo	~19.1 mo	~12	~R 31 334 PFS proxy · indirect	1
Dacarbazine monotherapy Variant #01	—	R 2 094	21d	—	~13.1 mo	—	—	4
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	~5.4 mo	~19.0 mo	~8	~R 10 346 PFS proxy · indirect	6
Cisplatin monotherapy Variant #16	—	R 650	28d	~1.4 mo	—	~2	~R 1 300 PFS proxy · indirect	1
Trabectedin monotherapy N/A - secondary systemic drug	—	R 109	28d	4.4 mo	—	5	R 543 PFS proxy	2

9 of 9 regimens shown